![](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ce049b7039345786f1091160bfdecb0b7ab30a77-1200x660.jpg?fit=crop&auto=format)
Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer
In January 2025, the FDA approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for patients with unresectable or metastatic hormone receptor (HR)–positive, HER2-low or HER2-ultralow breast cancer, based on findings from the phase 3 DESTINY-Breast06 …